JPRN-jRCT1030230197招募中Unknown
The association between pathogenic factors of Alzheimer's disease and sleep-dependent memory consolidation processes
Kuriyama Kenichi0 个研究点目标入组 50 人开始时间: 2023年7月1日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 60age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Participants who will participate to the AT-Sleep study (jRCT1031220550) are enrolled. Individual selection criteria for healthy volunteers and patients on the Alzheimer's disease (AD) spectrum (mild AD, mild cognitive impairment (MCI), and preclinical AD) are as follows;
- •Healthy volunteers
- •1. Normal cognitive function (MMSE score is 28 points or higher)
- •2. Comprehensive CDR score is 0
- •3. MRI and PET have already been performed or will be performed in the AT-Sleep study.
- •4. Polysomnography will be performed in the AT-Sleep study.
- •5. Participants must fully understand the study and give written consent of their own free will.
- •Patients with AD spectrum
- •(Common part)
- •1. The participants are currently attending our hospital or have a history of research participation, and meet one of the following criteria (A, B, and C.)
- •2. They fully understand the content of the research and give written consent of their own will.
- •3. They have a partner who contacts the participant at least once a week and is willing to participate in the study as an informant.
- •4. They maintain vision, hearing, and writing skills that do not affect cognitive function tests.
- •5. They have already performed MRI and PET or will perform in the AT-Sleep study.
- •6. They will undergo polysomnography in the AT-Sleep study.
- •a. Probable AD on NIAAA diagnostic criteria
- •b. MMSE score is 23 or less
- •c. 0.5 or 1 on the comprehensive CDR
- •B. MCI (due to AD)
- •a. MCI due to AD by NIAAA diagnostic criteria
- •b. MMSE score is 27 or less
- •c. Comprehensive CDR score is 0.5 with memory score is 0.5 or 1
- •C. Preclinical AD
- •a. Probable AD by NIAAA diagnostic criteria (previously participated in amyloid PET studies, and the amyloid positive finding have been revealed)
- •b. MMSE core is 28 points or higher
- •c. Comprehensive CDR score is 0
排除标准
- •Healthy volunteers
- •1. The participants who have been diagnosed certain neurodegenerative diseases or conditions including AD spectrum, also with multiple cerebral infarctions, normal pressure hydrocephalus, brain tumors, epilepsy, subdural hematoma, multiple sclerosis, or head trauma that results residual damage or abnormal brain structure.
- •2. They have a focal lesion, such as a cerebral infarction, that could affect infection or cognitive function on MRI.
- •3. They suffer from cardiac pacemakers, aneurysm clips, cochlear implants, other magnetic or electrically conductive metals, or claustrophobia that causes problems with MRI imaging.
- •4. They show hypersensitivity to thioflavin derivatives.
- •5. They have major depression or bipolar disorder defined by DSM-5 within the past year, or have a history of schizophrenia defined by DSM-5 in the past.
- •6. They have a history of alcohol or drug dependence defined by the DSM-5 within the past 2 years.
- •7. They have some sleep disorders under treatment.
- •8. They have a serious systemic illness or unstable conditions.
- •9. They are judged to be ineligible by the M.D. investigators.
- •Patients with AD spectrum
- •1. The participants have a specific neurodegenerative disease other than AD spectrum, including multiple cerebral infarctions, normal pressure hydrocephalus, brain tumor, epilepsy, subdural hematoma, multiple sclerosis, or head injury that has left residual effects or abnormal brain structure.
- •2. They have a focal lesion, such as a cerebral infarction, that could affect infection or cognitive function on MRI.
- •3. They suffer from cardiac pacemakers, aneurysm clips, cochlear implants, other magnetic or electrically conductive metals, or claustrophobia that causes problems with MRI imaging.
- •4. They show hypersensitivity to thioflavin derivatives.
- •5. They have major depression or bipolar disorder defined by DSM-5 within the past year, or have a history of schizophrenia defined by DSM-5 in the past.
- •6. They have a history of alcohol or drug dependence defined by the DSM-5 within the past 2 years.
- •7. They have exhibited psychiatric symptoms, excitability, and behavioral abnormalities to such an extent that adhering to the protocol has become difficult within the past 3 months.
- •8. They have a serious systemic illness or unstable conditions.
- •9. They have been admitted to a nursing home or hospital.
- •10. They are participating in a clinical intervention study or trial at the time of enrollment, or have a history of participation in anti-amyloid therapy trials.
- •11. They are judged to be ineligible by the M.D. investigators.
研究者
相似试验
尚未招募
不适用
Pathophysiological mechanisms and biomarkers of alopecia areataL63.9Alopecia areata, unspecifiedDRKS00032875Klinik für Dermatologie, Allergologie und Venerologie der MHH70
尚未招募
不适用
Analysis of relationships between pathogenesis of hematological diseases and activated plateletsHematological diseasesJPRN-UMIN000036644Tokai University Hachioji Hospital Department of Hematology/Oncology200
尚未招募
Unknown
Effect Of Hingvashtak Churna In AjirnaCTRI/2024/07/071390DrRamrao Ashok Patil
已完成
不适用
Analysis of association between disease of the oral cavity and IgA nephropathyIgA nephropathyJPRN-UMIN000017048Division of Nephrology, Seirei Hamamatsu General Hospital120
尚未招募
不适用
Endometrial cancer - factors affecting disease recurrenceCTRI/2021/04/032663Amrita Institute